市場調查報告書

全球抗血栓劑市場:成長,趨勢,預測(2020∼2025)

Antithrombotic Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 925313
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
全球抗血栓劑市場:成長,趨勢,預測(2020∼2025) Antithrombotic Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

抗血栓劑的全球市場,今後數年預計市場成長加速。新產品開發、上市,沒有抗血栓藥的替代品,預期推動這個市場成長,不過,嚴格法規政策與新藥的高成本,預計妨礙市場成長。

調查本報告提供全球抗血栓劑場,市場概要,各藥物、給藥途徑、用途、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素及市場機會分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 心臟病、遺傳性疾病的盛行率增加
    • 新的口服抗凝固藥和高齡化人口的需求高漲
  • 市場阻礙因素
    • 嚴格法規政策
    • 開發中國家的資源不足
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場區隔化

  • 各藥物
    • 血栓溶解藥
    • 抗血小板藥
    • 抗凝固劑
  • 各給藥途徑
    • 口服
    • 非口服
  • 各用途
    • 肺動脈栓塞
    • 深部靜脈血栓症
    • 心房纖維顫動
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Sanofi SA
    • Bayer AG
    • Eli Lilly and Company
    • AstraZeneca plc
    • CH Boehringer Sohn AG & Ko. KG
    • Otsuka Pharmaceutical Co., Ltd.
    • Novartis International AG
    • Aspen Holdings
    • Bristol-Myers Squibb Company

第7章 市場機會及未來趨勢

目錄
Product Code: 67846

Thrombosis is a condition when the blood clot is formed called a thrombus. Thrombus prevents the blood flow in blood vessels and may cause the death of cells and serious medical conditions. Antithrombotic drugs are used to prevent or treat thrombus formation. The growing number of chronic diseases that lead to thrombosis coupled with the increase in geriatric population is expected to drive the market growth. In addition, many of the drugs of antithrombotics are off-patented and presence of generics with a lower cost are fuelling the market growth over the forecast period. Furthermore, the presence of strong drug pipelines such as Tecarfarin, TB-402 and others and their expected commercialization is projected to boost the market growth over the coming years. Moreover, unavailability of alternatives for antithrombotic drugs coupled with the new product developments and launches are expected to bolster the market growth. However, stringent regulatory policies and high cost of novel drugs are expected to hamper the market growth.

Key Market Trends

Parental Route of Administration Expected to Have Significant Share

  • In the route of administration parenteral route is having significant share owing to its onset of action and presence of notable number of products in the market.
  • In the application segment, deep vein thrombosis is expected to have a healthy growth rate over the forecast period owing to its prevalence and sedentary lifestyle among the population that is leading to cardiovascular diseases.
  • According to the Center for Disease Control and Prevention (CDC), about 900,000 people each year affected by venous embolism. Furthermore, 10-30% of people will die within the month of diagnosis.
  • The advancements in treatment therapies such as catheter-directed thrombolysis and others in the usage of antithrombotic drugs for better clinical outcomes are projected to boost the market growth over the forecast period. In addition ageing population around the world is expected to boost the market growth.

North America Projected to Grow at Significant Rate

North America region is expected to have significant market growth over the forecast period. The high prevalence of cardiac diseases and cancer are expected to fuel the regional market share. In addition, favourable reimbursement policies and well-established healthcare infrastructure coupled with growing healthcare expenditure expected to boost the market growth in North America.

According to the World Health Organization, an estimated 17.9 million people died due to cardiovascular diseases in the year 2016. Out of these most of the deaths occured in Low-and Middle-income Countries. The Asia Pacific projected to have significant market growth owing to a large number of patient pool suffering from cardiac diseases and the presence of a strong generic drug market in emerging countries. In addition, manufactures interest in expanding to these Asian emerging countries expected to boost the market growth in the near future.

Competitive Landscape

Antithrombotic drugs market is highly competitive having a majority number of local or regional players. Market players are focusing on drug development, product launches and geographic expansions. Key market players operating in the market include Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Ko. KG and Aspen Holdings among the others

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Prevalence of Cardiac and Hereditary Diseases
    • 4.2.2 Growing Demand For Novel Oral Anticoagulants and Ageing Population
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Policies
    • 4.3.2 Lack of Resources in Underdeveloped Countries
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Thrombolytic Drugs
    • 5.1.2 Anti-platelet Drugs
    • 5.1.3 Anticoagulants
  • 5.2 By Route of Administration
    • 5.2.1 Oral
    • 5.2.2 Parenteral
  • 5.3 By Application
    • 5.3.1 Pulmonary Embolism
    • 5.3.2 Deep Vein Thrombosis
    • 5.3.3 Atrial Fibrillation
    • 5.3.4 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Sanofi S.A.
    • 6.1.2 Bayer AG
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 AstraZeneca plc
    • 6.1.5 C.H. Boehringer Sohn AG & Ko. KG
    • 6.1.6 Otsuka Pharmaceutical Co., Ltd.
    • 6.1.7 Novartis International AG
    • 6.1.8 Aspen Holdings
    • 6.1.9 Bristol-Myers Squibb Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS